43517_TS_Creating_an_Optimized_Gating_JM_990x120-1

Event Overview

Advances in flow cytometry increasingly rely on computational tools for discovery. However, workflows for cell sorting remain unchanged, using manual gating and subjective combinations of one- and two-dimensional gates that may not efficiently capture all phenotypes. Moreover, computational tools such as tSNE, uMAP, or clustering cannot be used to sort cells, limiting the isolation of complex cell populations. HyperFinder—a novel technology for optimizing gating sequences—addresses these limitations by alleviating speed, labor, and reproducibility bottlenecks for cell sorting in basic and clinical research.

In this LabTools webinar brought to you by BD Biosciences, Rafael Gomez-Amaro will explore how creating sort gates from flow cytometry clusters helps scientists identify and isolate cells for downstream assays.

Topics to be covered

  • How optimized sort gates from high-dimensional flow cytometry clusters inform robust cell phenotyping, sorting, and isolation
  • How HyperFinder overcomes the challenges of traditional flow cytometry analysis workflows to enable access to optimized gate sequences for cell identification and sorting

  • Wednesday, March 30, 2022

    2:30- 3:30 PM Eastern Time (11:30 AM-12:30 PST)

    This webinar will also be available on-demand.



    Meet the speakers

    Koonin.png
    Speaker
    Rafael Gomez-Amaro, PhD
    Scientific Advisor, High-Dimensional Biology
    BD Biosciences

    Niederkofler.png
    Moderator
    Karen Ersland, PhD
    Scientific Liaison
    Research Solutions at BD Biosciences

    Sponsored by

    thermo

    Register

    TS_Webinar_Bio-Rad_LabTools_Droplet Digital PCR: When qPCR Doesn’t Make the Cut November 4, 2021_IO#403220

    You must have Javascript and Cookies enabled to access this webcast.

    Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.